Axl受体酪氨酸激酶在非小细胞肺癌中的作用
Function of Axl receptor tyrosine kinase in non-small cell lung cancer.
作者信息
Zhang Guoan, Wang Meng, Zhao Hongli, Cui Wen
机构信息
Cancer Pathology Research Institute, Jining Medical University, Jining, Shandong 272067, P.R. China.
Department of Oncology, Shandong Jining First People's Hospital, Jining, Shandong 272111, P.R. China.
出版信息
Oncol Lett. 2018 Mar;15(3):2726-2734. doi: 10.3892/ol.2017.7694. Epub 2017 Dec 27.
Abstract
Axl receptor tyrosine kinase (hereafter Axl) is a member of the tyrosine-protein kinase receptor Tyro3, Axl and proto-oncogene tyrosine-protein kinase Mer family of receptor tyrosine kinases, possessing multiple different functions in normal cells. Axl is overexpressed and activated in numerous different human cancer types, triggering several signaling pathways and enhancing tumor progression. The present review assesses previous studies on the function of Axl in non-small cell lung cancer (NSCLC). Axl is overexpressed in the tumor tissues of a number of patients with NSCLC and is associated with poorer clinical outcomes; it promotes NSCLC tumor growth, invasion/metastasis, drug resistance and the epithelial-mesenchymal transition, thus providing a survival advantage to tumor cells. Therefore, Axl may be a promising target in NSCLC treatment.
摘要
Axl受体酪氨酸激酶（以下简称Axl）是酪氨酸蛋白激酶受体Tyro3、Axl和原癌基因酪氨酸蛋白激酶Mer家族的成员，在正常细胞中具有多种不同功能。Axl在多种不同类型的人类癌症中过度表达并被激活，触发多种信号通路并促进肿瘤进展。本综述评估了先前关于Axl在非小细胞肺癌（NSCLC）中功能的研究。Axl在许多NSCLC患者的肿瘤组织中过度表达，并与较差的临床结果相关；它促进NSCLC肿瘤生长、侵袭/转移、耐药性和上皮-间质转化，从而为肿瘤细胞提供生存优势。因此，Axl可能是NSCLC治疗中一个有前景的靶点。
相似文献
1
Function of Axl receptor tyrosine kinase in non-small cell lung cancer.Axl受体酪氨酸激酶在非小细胞肺癌中的作用
Oncol Lett. 2018 Mar;15(3):2726-2734. doi: 10.3892/ol.2017.7694. Epub 2017 Dec 27.
2
The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.AXL抑制剂在肺癌治疗中的发展：最新进展与挑战
Front Oncol. 2022 Mar 3;12:811247. doi: 10.3389/fonc.2022.811247. eCollection 2022.
3
AXL receptor tyrosine kinase as a therapeutic target in NSCLC.AXL受体酪氨酸激酶作为非小细胞肺癌的治疗靶点
Lung Cancer (Auckl). 2015 Apr 30;6:27-34. doi: 10.2147/LCTT.S60438. eCollection 2015.
4
The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications.受体酪氨酸激酶Axl在肿瘤发生及治疗耐药性发展中的作用：分子机制与未来应用概述
Cancers (Basel). 2021 Mar 25;13(7):1521. doi: 10.3390/cancers13071521.
5
Analysis of Tumor Heterogeneity Through AXL Activation in Primary Resistance to EGFR Tyrosine Kinase Inhibitors.通过AXL激活分析原发性EGFR酪氨酸激酶抑制剂耐药中的肿瘤异质性
JTO Clin Res Rep. 2023 May 12;4(6):100525. doi: 10.1016/j.jtocrr.2023.100525. eCollection 2023 Jun.
6
G-749 Promotes Receptor Tyrosine Kinase TYRO3 Degradation and Induces Apoptosis in Both Colon Cancer Cell Lines and Xenograft Mouse Models.G-749促进受体酪氨酸激酶TYRO3降解并在结肠癌细胞系和异种移植小鼠模型中诱导细胞凋亡。
Front Pharmacol. 2021 Oct 14;12:730241. doi: 10.3389/fphar.2021.730241. eCollection 2021.
7
Targeting MERTK and AXL in Mutant Non-Small Cell Lung Cancer.靶向突变型非小细胞肺癌中的MERTK和AXL
Cancers (Basel). 2021 Nov 11;13(22):5639. doi: 10.3390/cancers13225639.
8
AXL transcriptionally up-regulates TMEM14A expression to mediate cell proliferation in non-small-cell lung cancer cells.AXL 通过转录上调 TMEM14A 的表达来介导非小细胞肺癌细胞的增殖。
Biochem Biophys Res Commun. 2023 Nov 19;682:365-370. doi: 10.1016/j.bbrc.2023.10.027. Epub 2023 Oct 7.
9
Effect of AXL on the epithelial-to-mesenchymal transition in non-small cell lung cancer.AXL对非小细胞肺癌上皮-间质转化的影响。
Exp Ther Med. 2017 Jul;14(1):785-790. doi: 10.3892/etm.2017.4532. Epub 2017 Jun 1.
10
Mechanisms of resistance to EGFR tyrosine kinase inhibitors.表皮生长因子受体酪氨酸激酶抑制剂的耐药机制。
Acta Pharm Sin B. 2015 Sep;5(5):390-401. doi: 10.1016/j.apsb.2015.07.001. Epub 2015 Jul 26.
引用本文的文献
1
Targeting AXL can effectively overcome c-Met-induced therapeutic resistance in renal cancer and promote tumor cell death through increased oxidative stress.靶向AXL可有效克服c-Met诱导的肾癌治疗耐药性，并通过增加氧化应激促进肿瘤细胞死亡。
Cancer Lett. 2025 Aug 18;633:217984. doi: 10.1016/j.canlet.2025.217984.
2
Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine.弥合差距：患者来源的肺癌类器官如何改变个性化医疗。
Front Cell Dev Biol. 2025 Apr 15;13:1554268. doi: 10.3389/fcell.2025.1554268. eCollection 2025.
3
Recent advances in TAM mechanisms in lung diseases.肺部疾病中肿瘤相关巨噬细胞（TAM）机制的最新进展。
J Transl Med. 2025 Apr 26;23(1):479. doi: 10.1186/s12967-025-06398-2.
4
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer.克服表皮生长因子受体（EGFR）突变型肺癌对奥希替尼耐药的策略
Int J Mol Sci. 2025 Mar 25;26(7):2957. doi: 10.3390/ijms26072957.
5
The role of tumor-associated macrophages in lung cancer.肿瘤相关巨噬细胞在肺癌中的作用。
Front Immunol. 2025 Feb 26;16:1556209. doi: 10.3389/fimmu.2025.1556209. eCollection 2025.
6
Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.丹佛替尼通过NLRP3炎性小体激活效应T细胞，与帕博利珠单抗联合使用可产生强大的抗癌效果。
Mol Cancer Ther. 2025 Mar 4;24(3):354-369. doi: 10.1158/1535-7163.MCT-24-0501.
7
AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies.AXL作为急性髓系白血病中的免疫调节因子和治疗靶点：从当前进展到新策略
Exp Hematol Oncol. 2024 Oct 4;13(1):99. doi: 10.1186/s40164-024-00566-8.
8
Exploring the Potential of Antibody-Drug Conjugates in Targeting Non-small Cell Lung Cancer Biomarkers.探索抗体药物偶联物在靶向非小细胞肺癌生物标志物方面的潜力。
Clin Med Insights Oncol. 2024 Jun 22;18:11795549241260534. doi: 10.1177/11795549241260534. eCollection 2024.
9
Identification of a novel DNA repair inhibitor using an in silico driven approach shows effective combinatorial activity with genotoxic agents against multidrug-resistant Escherichia coli.利用计算机驱动的方法鉴定新型 DNA 修复抑制剂，显示其与遗传毒性药物联合使用对多药耐药大肠杆菌具有有效的组合活性。
Protein Sci. 2024 Apr;33(4):e4948. doi: 10.1002/pro.4948.
10
Role of STAT3 in cancer cell epithelial‑mesenchymal transition (Review).STAT3 在癌细胞上皮-间充质转化中的作用（综述）。
Int J Oncol. 2024 May;64(5). doi: 10.3892/ijo.2024.5636. Epub 2024 Mar 15.
本文引用的文献
1
AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity.AXL受体酪氨酸激酶是T细胞启动和抗病毒免疫所必需的。
Elife. 2016 Jun 28;5:e12414. doi: 10.7554/eLife.12414.
2
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer.Axl受体轴：肺癌中的一个新治疗靶点。
J Thorac Oncol. 2016 Aug;11(8):1357-1362. doi: 10.1016/j.jtho.2016.04.015. Epub 2016 Apr 26.
3
Insights into the roles of hnRNP A2/B1 and AXL in non-small cell lung cancer.对异质性核糖核蛋白A2/B1和AXL在非小细胞肺癌中作用的见解。
Oncol Lett. 2015 Sep;10(3):1677-1685. doi: 10.3892/ol.2015.3457. Epub 2015 Jul 3.
4
Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance.上皮-间质转化并非肺转移所必需，但会导致化疗耐药。
Nature. 2015 Nov 26;527(7579):472-6. doi: 10.1038/nature15748. Epub 2015 Nov 11.
5
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer.上皮-间质转化对胰腺癌转移并非必需，但可诱导其产生化疗耐药性。
Nature. 2015 Nov 26;527(7579):525-530. doi: 10.1038/nature16064. Epub 2015 Nov 11.
6
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective.AXL 抑制剂在癌症治疗中的应用：从药物化学角度看
J Med Chem. 2016 Apr 28;59(8):3593-608. doi: 10.1021/acs.jmedchem.5b01273. Epub 2015 Nov 20.
7
Coexpression of receptor tyrosine kinase AXL and EGFR in human primary lung adenocarcinomas.受体酪氨酸激酶AXL与表皮生长因子受体（EGFR）在人原发性肺腺癌中的共表达
Hum Pathol. 2015 Dec;46(12):1935-44. doi: 10.1016/j.humpath.2015.08.014. Epub 2015 Sep 15.
8
Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells.全激酶组 shRNA 筛选发现受体酪氨酸激酶 AXL 是间质型神经胶质瘤干细胞样细胞的关键调节因子。
Stem Cell Reports. 2015 May 12;4(5):899-913. doi: 10.1016/j.stemcr.2015.03.005. Epub 2015 Apr 23.
9
AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas.AXL通过激活头颈部和食管鳞状细胞癌中的EGFR/PKC/mTOR轴介导对PI3Kα抑制的抗性。
Cancer Cell. 2015 Apr 13;27(4):533-46. doi: 10.1016/j.ccell.2015.03.010.
10
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.AUY922有效克服了肺癌细胞中MET和AXL介导的对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）的耐药性。
PLoS One. 2015 Mar 17;10(3):e0119832. doi: 10.1371/journal.pone.0119832. eCollection 2015.
Zotero 插件